Cardiogen vs Vesugen
A side-by-side research comparison of Cardiogen and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardiogen | Vesugen |
|---|---|---|
| Full name | Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research compound (peptide bioregulator) | Research compound (peptide bioregulator) |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | ~460 Da | ~390 Da |
| Half-life | Short (peptide) | Short (peptide) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Oral (encapsulated) or subcutaneous |
| Typical dose | ~1-2 capsules/day or short injectable courses | ~1-2 capsules/day or short injectable courses |
| Frequency | Once daily | Once daily |
| Route | Oral capsule or subcutaneous | Oral capsule or subcutaneous |
Cardiogen reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.